---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-058706"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2026-05-11T20:43:06+00:00"
generated_at: "2026-05-11T20:46:53.036790+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# ArriVent BioPharma expands at-the-market equity program by up to $250M

## Summary
- Filed prospectus supplement on May 11, 2026 to sell up to $250,000,000 of common stock via ATM.
- Jefferies LLC named as sales agent under existing Open Market Sale Agreement dated Feb 3, 2025.
- Proceeds will be used for general corporate purposes; no specific use disclosed.
- Offering is made under automatic shelf registration statement (Form S-3ASR, File 333-284661).

## SEC filing metadata
- accession: 0001104659-26-058706
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2026-05-11T20:43:06+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/0001104659-26-058706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000110465926058706/tm2614177d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-058706
- JSON: https://secwatch.observer/filing/0001104659-26-058706.json
- Plain text: https://secwatch.observer/filing/0001104659-26-058706.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.